Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ansbert Gadicke Sells 114,044 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 114,044 shares of the firm’s stock in a transaction dated Friday, October 31st. The shares were sold at an average price of $1.28, for a total value of $145,976.32. Following the sale, the insider owned 6,241,673 shares in the company, valued at approximately $7,989,341.44. The trade was a 1.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Monday, November 3rd, Ansbert Gadicke sold 94,063 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total value of $121,341.27.
• On Thursday, October 30th, Ansbert Gadicke sold 86,936 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.43, for a total value of $124,318.48.
• On Wednesday, October 29th, Ansbert Gadicke sold 134,240 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.55, for a total value of $208,072.00.
• On Tuesday, October 28th, Ansbert Gadicke sold 69,068 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.64, for a total value of $113,271.52.
• On Monday, October 27th, Ansbert Gadicke sold 72,709 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.72, for a total value of $125,059.48.

Werewolf Therapeutics Price Performance

HOWL stock opened at $1.31 on Tuesday. The company has a quick ratio of 5.30, a current ratio of 5.30 and a debt-to-equity ratio of 0.60. Werewolf Therapeutics, Inc. has a 52-week low of $0.60 and a 52-week high of $2.52. The stock’s 50 day moving average is $1.62 and its two-hundred day moving average is $1.32. The company has a market capitalization of $59.91 million, a PE ratio of -0.80 and a beta of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.10. Analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors have recently made changes to their positions in the company. Quadrature Capital Ltd bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter valued at approximately $28,000. Vontobel Holding Ltd. acquired a new position in Werewolf Therapeutics during the 1st quarter valued at approximately $34,000. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics during the 2nd quarter valued at approximately $48,000. Nuveen LLC acquired a new position in Werewolf Therapeutics during the 1st quarter valued at approximately $71,000. Finally, AQR Capital Management LLC acquired a new position in Werewolf Therapeutics during the 1st quarter valued at approximately $79,000. 64.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on HOWL shares. JMP Securities dropped their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. Bank of America dropped their price objective on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Citigroup reiterated a “buy” rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th. Finally, Zacks Research upgraded Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.